Loading
The 2026 journal summary of the US NCCN breast cancer guideline, this version focused on recurrent and metastatic disease and how treatment is chosen by receptor status, prior therapy and time since treatment.
Journal summary of the NCCN Clinical Practice Guidelines for Breast Cancer, version 4.2026, by Gradishar, Moran, Abraham, Abramson and colleagues. The guidelines cover carcinoma in situ, invasive breast cancer, Paget's disease, phyllodes tumour, inflammatory breast cancer and breast cancer in pregnancy; the panel convenes annually. This selection concentrates on recurrent or stage IV (M1) disease and summarises treatment stratified by hormone receptor status and HER2 expression, prior therapy and disease-free interval, with supportive care, quality of life, toxicity minimisation and trial participation emphasised throughout. The NCCN category grades quoted on the triple-negative page (category 1, preferred for the KEYNOTE-522 regimen and for first-line sacituzumab govitecan with pembrolizumab) come from the full guideline.
NCCN is the source of the category grades on the triple-negative breast cancer page and the first major guideline to place an antibody-drug conjugate first line for the disease.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares ASCENT-03, TROPION-Breast02, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.